PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis.
Tamara Kay MoyoAshwin KishtagariMatthew VillaumeBrandon J McMahonSanjay R MohanTess StopczynskiSheau-Chiann ChenRun FanYuankai HuoHyeonsoo MoonYucheng TangCosmin A BejanMerrida ChildressIngrid A AndersonKyle RawlingRhea M SimonsAshley MoncriefRebekah CazaLaura DuggerAunshka CollinsChanning V DudleyPaul Brent FerrellMichael T ByrneStephen A StricklandGregory D AyersBennett A LandmanEmily F MasonRuben A MesaJeanne M PalmerLaura C MichaelisMichael R SavonaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Adding umbralisib to ruxolitinib in patients was well-tolerated and may re-sensitize MF patients to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors.